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Abstract:  
 Introduction: In 2012, GOLD revised their 
classification of Chronic Obstructive Pulmonary Disease 
patients, incorporating spirometry, symptoms and recent 
exacerbations.1 
Aims and Objectives: To assess if patients 
admitted with an exacerbation of COPD were properly 
staged prior to the admission, and whether their 
treatment on presentation was in accordance with GOLD 
recommendations. 
Materials and Methods: All patients admitted to 
Mater Dei Hospital, Malta with a COPD exacerbation 
during February, May and August 2013 were studied. 
Spirometry was considered relevant if performed within 
the previous two years. The mMRC score of each 
patient, the number of exacerbations over the previous 
12 months, and patient co-morbidities were also 
recorded. 
 
 
Results: A total of 124 patients were admitted with 
an exacerbation during the study period. Of the patients 
who were known to have COPD, only 48.5% had 
spirometry performed in the previous two years. Most 
patients admitted were in GOLD Stage 3 (34.0%), and 
most were classified as GOLD Group D (73.2%). A long 
acting bronchodilator was not prescribed in 48.8% of 
cases where it was indicated. An inhaled corticosteroid 
was not prescribed in 25.6% of cases where it was 
indicated, while 10.3% of patients were prescribed an 
inhaled corticosteroid when this was not indicated. 
Conclusion: It is noted that there is a need to 
improve diagnosis and treatment of COPD on a local 
basis. 
 
Introduction 
The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) maintains that Chronic Obstructive 
Pulmonary Disease (COPD) is a clinical diagnosis that 
should be based on history-taking, the presence of 
symptoms and assessment of airway obstruction. GOLD 
recommends spirometry as the gold standard for 
accurate and repeatable measurement of airway 
obstruction, measured as the post-bronchodilator Forced 
Expiratory Volume in one second (FEV1). GOLD 
regards a FEV1/FVC ratio (Forced Expiratory Volume in 
one second / Forced Vital Capacity) of less than 0.70 as 
compatible with COPD. 
It was previously believed that most COPD patients 
followed a path of disease progression in which the 
severity of the disease process paralleled the severity of 
the airflow limitation. However, more recent studies 
have shown that on an individual patient basis, the level 
of airflow limitation (FEV1) on its own is an unreliable 
marker of the severity of breathlessness, exercise 
limitation, and health status impairment. This has led 
GOLD to revise its guidelines in 2011, presenting a new 
way of assessing COPD patients, taking into account 
level of patient’s symptoms, severity of airflow 
limitation, and recent exacerbations, as well as the 
presence of comorbidities. The most recent GOLD 
update from January 2015 has retained this combined 
level of assessment.1 
Current GOLD recommendations and its 
implementation within hospitalised COPD 
patients in Malta 
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The first aim of our audit was to check if patients 
admitted to Mater Dei Hospital with an exacerbation of 
COPD, were staged by spirometry at any point during 
the previous two years. Secondly, the audit aimed to 
compare the treatment on admission of each patient, 
with that recommended by GOLD guidelines for the 
particular GOLD patient group in question. 
                     
Materials and Methods 
Inclusion and Exclusion Criteria 
All patients admitted to Mater Dei Hospital with an 
exacerbation of COPD during February, May and 
August 2013 were included in the study. Those patients 
who were newly diagnosed with COPD and those who 
were not previously residing in Malta prior to the 
admission, were excluded from the rest of study, 
because understandably no previous spirometry would 
be available in the Mater Dei Hospital records. 
 
Current Level of Patient’s Symptoms 
The modified Medical Research Council Dyspnoea 
Score (mMRC) was used to assess patient symptoms. 
The patients were contacted and asked how they would 
rank themselves on the mMRC score in the month 
preceding the hospital admission, rather than the last few 
days prior to admission. This is because the GOLD 
guidelines being highlighted by this audit, are focused 
on the management of stable COPD, not the actual 
exacerbation. 
 
Severity of the Airflow Limitation 
The post-bronchodilator Forced Expiratory Volume 
in one second (FEV1) was used as the measurement of 
airway limitation. The FEV1 readings were considered to 
be valid if they were recorded at any point during the 
previous two years. Spirometry performed prior to this 
arbitrary two-year period, was considered to be old and 
not an accurate reflection of the patient’s airflow 
limitation during the period immediately prior to the 
COPD exacerbation. Using the FEV1 from spirometry 
carried out during the hospital admission (if any) was 
not considered appropriate since the GOLD guidelines 
being highlighted by this audit, are centred on the 
management of stable COPD, not the actual 
exacerbation. The FEV1/FVC ratio of each patient was 
also checked, since a ratio of more than 0.70 is not 
compatible with COPD. Table 1 shows the GOLD 
classification system used. 
 
Recent Exacerbations 
The number of COPD exacerbations leading to 
hospitalisation in the preceding 12 months for each 
patient was obtained from the Mater Dei Hospital 
Electronic Case Summary database. Each patient was 
then called in order to collect data on the number of 
exacerbations which did not lead to hospitalisation. 
Table 1: GOLD Stages 
 
 
 
 
 
 
 
 
 
 
 
 
GOLD = Global initiative for chronic Obstructive Lung 
Disease,  
FEV1 = Forced Expiratory Volume in one second 
 
Presence of Co-morbidities 
Patient co-morbidities were obtained from the 
discharge summary available on the Mater Dei Hospital 
Electronic Case Summary database.  
 
Combined Assessment of COPD 
Each patient was classified into a GOLD patient 
group by combining airflow limitation (spirometry), 
symptoms and recent exacerbations, as shown in Table 
2. 
 
Table 2: Combined Assessment of COPD 
GOLD 
Group 
Symptoms 
Airflow 
Limitation 
Exacerbations 
over past 12 
months 
A 
mMRC 
0-1 
Low Risk 
Stage 1 or 
2 
Low Risk 
0 or 1 not leading 
to hospitalisation 
B mMRC ≥2 
Low Risk 
Stage 1 or 
2 
Low Risk 
0 or 1 not leading 
to hospitalisation 
C 
mMRC 
0-1 
High Risk 
Stage 3 or 
4 
High Risk 
≥2    or                 
≥1 leading to 
hospitalisation 
D mMRC ≥2 
High Risk 
Stage 3 or 
4 
High Risk 
≥2    or                 
≥1 leading to 
hospitalisation 
GOLD = Global initiative for chronic Obstructive Lung 
Disease,  
mMRC = modified Medical Research Council dyspnoea score 
GOLD Stage 1 – post-bronchodilator FEV1 ≥ 80% 
predicted 
GOLD Stage 2 – post-bronchodilator FEV1 50 to 
80% predicted 
GOLD Stage 3 – post-bronchodilator FEV1 30 to 
50% predicted 
GOLD Stage 4 – post-bronchodilator FEV1 < 30% 
predicted 
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When assessing risk, the highest risk according to 
airflow limitation or exacerbation history should be 
used. For example, a patient with a mMRC score of 1 
with a post-bronchodilator FEV1 of 70% (therefore Gold 
Stage 2) and 2 exacerbations over the past year, was 
classified as Group C. 
 
Pharmacologic Therapy for Stable COPD 
The patients were asked what treatment they were 
taking prior to the admission, and this was compared to 
that recommended by GOLD. The Recommended First 
Choice and the Alternative Choice were considered 
optimal for the particular GOLD group in question 
(Table 3). The treatment options listed in the Other 
Possible Treatments section of the GOLD guidelines, 
were not considered optimal.  
 
Table 3: Optimal Pharmacological Therapy 
GOLD 
Group 
Recommended 
First Choice 
Alternative 
Choice 
      
A SAMA prn or LAMA or 
  SABA prn LABA or 
  
 
SAMA + SABA 
  
  
B LAMA or LAMA + LABA 
  LABA 
 
  
  
C ICS + LABA or LAMA + LABA or 
  LAMA 
LAMA + PDE-4 inhibitor 
or 
  
 
LABA + PDE-4 inhibitor 
  
  
D 
ICS + LABA 
and/or LAMA 
ICS + LABA + LAMA or 
  
 
ICS + LABA + PDE-4 
inhibitor or 
  
 
LAMA + LABA or 
  
 
LAMA + PDE-4 inhibitor 
 
SAMA = short-acting anti-muscarinic agent,  
SABA = short-acting beta-agonist,  
LAMA = long-acting anti-muscarinic agent,  
LABA = long-acting beta-agonist,  
ICS = inhaled corticosteroid,  
PDE-4 = phosphodiesterase type 4 
 
 
Results 
Patient Demographics 
A total of 124 patients were admitted with a COPD 
exacerbation during the study period. 57 patients were 
admitted in February, 40 in May, and 27 in August 2013. 
The patient age ranged from 40 to 98 years, with a mean 
of 70 years and a median of 71 years.  The length of 
admission ranged from 1 to 25 days, with a mean of 5.9 
days and a median of 5 days. 
 
Current Level of Patient’s Symptoms 
Fig. 1 shows the distribution of patient according to 
mMRC score. 
 
Severity of the Airflow Limitation 
Table 4 shows that 48 patients (38.7%) had valid 
spirometry, i.e. performed in the last two years. After 
eliminating the newly-diagnosed COPD patients and 
those not previously residing in Malta, only 48 patients 
(48.5%) were found to have valid spirometry. Of these 
patients, 34.0% were classified as Stage 3. Both Stage 2 
and 4 comprised 27.7% of patients, while 10.6% were 
classified as Stage 1. 
 
Recent Exacerbations 
The mean number of exacerbations per patient over 
the past 12 months, was 1.2. The range was 0 to 14. 67 
patients (54.0%) were classified as Low Risk, meaning 
they had 0 or 1 exacerbations over the past 12 months, 
which did not lead to hospitalisation. 57 patients 
(46.0%) were High Risk, having at least 2 exacerbations 
over the past 12 months, or at least one exacerbation 
which led to hospitalisation. 
 
Presence of Co-morbidities 
COPD was found to be highly co-morbid with a 
number of disorders, as shown in Fig. 2. 
 
Combined Assessment of COPD 
Fig. 1 shows the distribution of patients according 
to GOLD group, with 73.2% of patients being classified 
as Group D.  
 
Pharmacologic Therapy for Stable COPD 
The treatment of only 14 patients (36.0%) was in 
accordance with the first recommended choice or the 
alternative choice recommended by GOLD. The 
remaining 64.0% of patients were not on optimal 
therapy. Inhaled long-acting beta-agonist (LABA) 
treatment is recommended for all patients in Group B to 
D, of which 48.8% were not receiving LABA therapy. 
Inhaled corticosteroid therapy (ICS) is recommended for 
all patients in Group C and D, of which 25.6% were not 
on ICS treatment. On the other hand, 10.3% of patients 
in Groups A and B were on ICS therapy, when this is not 
recommended by GOLD (Fig. 3).  
35
  
 
 
 
Original Article  
 
Malta Medical Journal    Volume 27 Issue 01 2015                                                                                                                
 
 
12.2%
4.9%
8.9%
12.2%
10.0% 9.8%
68.9%
73.2%
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
mMRC
Grade 1
GOLD
Group A
mMRC
Grade 2
GOLD
Group B
mMRC
Grade 3
GOLD
Goup C
mMRC
Grade 4
GOLD
Group D
 
Figure 1: Patient Symptoms and GOLD Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mMRC = modified Medical Research Council dyspnoea score,   
GOLD = Global initiative for chronic Obstructive Lung Disease 
 
 
Table 4: Validity of Spirometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spirometry Percentage 
Spirometry in last 2 years 38.7% 
Spirometry more than 2 years ago 11.3% 
No Spirometry done since migration to MDH 29.8% 
New diagnosis of COPD 16.1% 
Non-Residents 4.0% 
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Figure 2: Presence of Co-morbidities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Pharmacological Therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LABA = long-acting beta agonist,  
ICS = inhaled corticosteroid 
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Discussion 
The results obtained from this local audit are 
comparable to the figures from the 2010 European 
COPD Audit, which was an observational multicentre 
study, collecting data from 15821 patients in 422 
hospitals around Europe, including Mater Dei Hospital, 
with the aim of assessing hospital care for COPD 
patients.2 The number of patients in the local study was 
124, with a median age of 68, while the number of 
Maltese patients included in the European study was 
112, with a median age of 72 years. The median length 
of hospital stay for an exacerbation of COPD in Malta 
was found to be 5 days in both studies, when compared 
to 8 days for Europe as a whole. The mean number of 
exacerbations per patient over the previous year was 1.2 
in the local study, similar to the median number for 
Europe, which was 1.  
Our present audit found that 48.5% of patients 
admitted with a COPD exacerbation had spirometry in 
the last 2 years. This was almost identical to the figure 
reported in the European audit for Malta - 48.2% - 
though this figure included any previous spirometry, not 
only that performed in the previous 2 years. The mean 
European figure was 59.6%, meaning that Malta was 
more than 10% below the mean. While our own figures 
for stratification of severity are very similar to the 2010 
total European figures, they were however quite 
different from the 2010 Maltese figures (Table 5). 
 
Table 5: Comparison of COPD Severity Stratification 
Data 
 
GOLD 
Stage 
 
Gauci et al. 
(2013) 
 
Malta 
 
 
European 
COPD 
Audit 
(2010) 
 
Europe 
 
 
European 
COPD Audit 
(2010) 
 
Malta 
 
Stage 1 10.6% 15.3% 46.3% 
Stage 2 27.7% 23.3% 5.6% 
Stage 3 34.0% 39.3% 24.1% 
Stage 4 27.7% 22.1% 24.1% 
 
 
 
 
Inadequate staging of COPD patients in Malta is 
primarily due to a lack of spirometry requests. There are 
several possible reasons for this. A 2013 qualitative 
study in Chicago concluded that the most common 
explanation behind primary care physicians not 
requesting spirometry, was that spirometry was deemed 
not necessary to make a clinical diagnosis of COPD.3 
GOLD maintains that spirometry is required for the 
diagnosis of COPD, and states that primary care 
physicians are in an ideal position to be able to detect 
COPD in its early stages and perform spirometry to 
confirm the diagnosis.1  
Research has shown that the primary benefit of 
spirometry is to identify those symptomatic patients who 
might benefit from pharmacological therapy in order to 
decrease frequency of exacerbations. However, 
monitoring with spirometry to guide additional therapy 
or to initiate interventions in patients without 
bothersome respiratory symptoms does not appear to be 
beneficial.4 
The local audit found that underprescription of 
inhaled LABA was common in Malta. The European 
study showed a very wide variation in the percentage of 
COPD patients who were receiving a LABA prior to 
admission, ranging from 0.6% to 45.9%.2 The mean 
value for Europe was 9.3%, and the value quoted for 
Malta was 12.5%, meaning that LABAs are also 
underprescribed in several other European countries. 
Our audit also described inappropriate prescription of 
ICS in mild COPD and underprescription in severe 
COPD. The European study looked at the percentage of 
COPD patients who were receiving ICS, and gave a 
mean value of 12.4% for Europe, and a value of 54.5% 
for Malta. Malta was in fact the country where ICS were 
most prescribed, by almost 20%. 
One possible reason for suboptimal 
pharmacological treatment is the lack of clear evidence 
that optimization of therapy improves outcomes in 
COPD. The 2015 systematic literature review carried out 
by Wilt et al. concluded that pharmacological 
interventions reduced the relative risk of exacerbations 
by 20 to 25%, and reduced hospitalisations by 4 to 7%, 
while mortality was not significantly different.4 The 
review concluded that the primary benefit of 
pharmacological intervention is to reduce exacerbations 
in patients with troublesome respiratory symptoms and 
severe to very severe airflow obstruction (FEV1 < 50% 
predicted).  
Another possible explanation behind 
underprescription is the fear of side-effects. LABA 
therapy could have been purposely avoided in patients 
with cardiac co-morbidities, because beta-agonists are 
associated with an increased risk in these patients. Au et 
al. described a dose-response relationship of increased 
hospitalisation and death due to heart failure in patients 
with congestive heart failure who received increasing 
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amounts of beta-agonist.5 On the other hand, there 
appeared to be no association between the use of inhaled 
beta-agonists and the risk of developing congestive heart 
failure. Studies specifically investigating the 
cardiovascular safety of LABAs have shown that both 
formoterol and salmeterol have a good cardiovascular 
safety profile6. GOLD also maintains that there is no 
evidence that COPD should be treated differently in the 
presence of IHD or CHF, but recommends avoidance of 
high doses of beta-agonists in unstable angina, as well as 
closer monitoring for patients with CHF.1 
Inhaled corticosteroids are being inadvertently 
prescribed in patients with mild COPD, possibly because 
of them being wrongly diagnosed as asthmatics. 
Although the role of Asthma & COPD Overlap 
Syndrome (ACOS) is becoming more evident, we must 
consider tailing off ICS gradually in mild to moderate 
COPD patients (Groups A and B). On the other hand, 
GOLD recommends adding ICS to our more severe 
COPD pts (Groups C and D) as this has been shown to 
decrease hospitalisation and exacerbations in these 
patients.1 Because of increasing concern about the long-
term safety of ICS use in COPD patients, the WISDOM 
study has evaluated the need for ICS use in severe 
COPD, via stepwise withdrawal of ICS in COPD 
patients in Stage 3 and 4 on dual bronchodilation 
(ICS+LABA).7 
 
Limitations of the Study 
Those patients who were not contactable for the 
purpose of enquiring about patient symptoms, were 
excluded from the rest of the analysis. This included 
those patients who were deceased, who were probably 
more likely to be patients from Group D, meaning that 
the sickest patients may have been excluded from the 
study.  
Spirometry was considered valid if performed 
during the previous two years. Patients who were 
classified as Stage 4 on spirometry more than two years 
previously, may purposely not have had repeat 
spirometry booked since there is little or no gain from 
restaging a patient who is already known to be end-stage 
in a progressive disorder such as COPD, meaning that 
once again, the sickest patients may have been excluded 
from the study. 
 
Recommendations for Malta 
The audit concludes that the staging of COPD 
patients in Malta should be improved. There is a need 
for increased awareness about the role of spirometry in 
the diagnosis and staging of COPD. This is especially 
important in those patients with bothersome respiratory 
symptoms since the primary benefit of spirometry is to 
identify those symptomatic patients who might benefit 
from pharmacological therapy in order to decrease 
frequency of exacerbations.  
Increased access to spirometry in Malta would 
facilitate the staging of COPD. The introduction of 
spirometers at Health Centres would be beneficial since 
primary care physicians are in an ideal position to be 
able to detect COPD in its early stages and perform 
spirometry to confirm the diagnosis. 
The audit emphasizes the importance of classifying 
COPD patients into GOLD Group A to D, based on 
spirometry, symptoms and recent exacerbations. There is 
a need for increased awareness among doctors working 
in Malta about the updated GOLD guidelines. This 
would then allow Maltese patients to be offered the 
optimal pharmacological therapy in accordance with the 
GOLD recommendations for each GOLD patient group. 
This is particularly beneficial in reducing exacerbations 
in patients with troublesome respiratory symptoms and 
severe to very severe airflow obstruction (FEV1 < 50% 
predicted), thereby reducing the burden of medical 
admissions to Mater Dei Hospital. 
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